Results 111 to 120 of about 13,497 (214)

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Acute GIP and GLP‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7280-7290, August 2026.
ABSTRACT Aims While being recognised for stimulating pancreatic insulin secretion, GIP and GLP‐1 exert various extrapancreatic effects relevant in the context of incretin‐based therapies. Here, we evaluated the extrapancreatic effects of GIP and GLP‐1, separately and combined, on postprandial physiology in totally pancreatectomised individuals ...
Liva S. L. Krogh, Maja B. Hansen, Natasha C. Bergmann, Carsten P. Hansen, Bolette Hartmann, Jens J. Holst, Filip K. Knop, Asger B. Lund, Lærke S. Gasbjerg   +8 more
wiley   +1 more source

Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7380-7392, August 2026.
ABSTRACT Aims This study aimed to assess the effects of low‐dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). Materials and Methods Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET ...
Zhuoran Yang, Yuxin Xu, Hu Du, Wenya Liu, Haiyan Chen, Dongfang Liu, Lili Zhang, Cong Wang   +7 more
wiley   +1 more source

Tirzepatide‐Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Tirzepatide dose escalation may precipitate functional small bowel obstruction that mimics mechanical obstruction, even in surgically naïve patients. Careful medication review and objective tools such as the water‐soluble contrast challenge can support safe non‐operative management and help avoid unnecessary surgical intervention.
Takuto Shimada, Yoshihiro Nose, Hiroki Tojima, Takahiro Maehata, Akitoshi Kato   +4 more
wiley   +1 more source

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Tirzepatide 15 mg and cagrilintide–semaglutide (CagriSema) achieve the greatest percent body weight reduction (−17.97% and −17.46%, respectively) and the highest rates of ≥ 20% weight loss versus placebo in this network meta‐analysis of 25 randomized trials.
Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu‐Khazneh, Celina R. Andonie, Saleem Majadleh, Anwar Zahran, Hazem Ayesh   +6 more
wiley   +1 more source

Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
In a real‐world setting, 12‐month imeglimin therapy in Japanese patients with type 2 diabetes provided sustained glycemic improvements and enhanced endogenous insulin secretion. Importantly, these durable metabolic benefits were achieved without requiring an increase in overall glucose‐lowering treatment intensity.
Yohei Fujita, Shuji Suganami, Yuka Morita, Toshio Matsui, Masahisa Hata, Masahiro Hatazaki   +5 more
wiley   +1 more source

In silico prediction and structural characterization of multifunctional bioactive peptides released from olive proteins

Journal of the Science of Food and Agriculture, Volume 106, Issue 9, Page 5463-5482, July 2026.
Abstract BACKGROUND Olive (Olea europaea L.) byproducts, such as seeds and leaves, are abundant agro‐industrial residues and represent underexplored protein sources with potential health relevance. However, the repertoire of bioactive peptides that may be released from olive proteins during gastrointestinal digestion remains poorly characterized.
Teresa Gonzalez‐de la Rosa, Luna Barrera‐Chamorro, Africa Fernandez‐Prior, Elvira Marquez‐Paradas, Maria Torrecillas‐Lopez, Fernando Rivero‐Pino, Sergio Montserrat‐de la Paz   +6 more
wiley   +1 more source

Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review

Journal of Diabetes, Volume 18, Issue 7, July 2026.
RCTs of incretin‐based treatment show effective weight loss and glycemic benefit, as well as improved CV outcomes. There is, however, uncertainty as to whether the RCTs translate to real‐world outcomes. This narrative review suggests real‐world outcomes are comparable to RCTs after accounting for submaximal dosing and high discontinuation rates ...
Zachary Bloomgarden
wiley   +1 more source

Interplay of the ENS and Microbiota With Murine Gut Epithelium‐Derived Organoids in Aging

Aging Cell, Volume 25, Issue 7, July 2026.
A gut organoid model was developed to study the impact of age‐related changes of the enteric nervous system (ENS) and microbiome on the integrity and trophic capacity of the intestinal epithelial barrier. Organoids reflected in vivo aging features, including altered epithelial integrity and changes in acetylcholine‐related enzyme activity.
Tinh Thi Nguyen, Dennis Schapelhouman, Katharina Fischer, Jia‐Xuan Chen, Mario Dejung, Fridolin Kielisch, Julia Varga, Johannes Piepgras, Matthew Ahn, Oliver Tüscher, Peter Baumann, Sandra Schick, Kristina Endres   +12 more
wiley   +1 more source

Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists. [PDF]

J Diabetes Investig
Kubota S, Seino Y, Yabe D.
europepmc   +1 more source